We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

4 hedge funds and large institutions have $208K invested in XTL Biopharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more capital invested

Capital invested by funds: $194K → $208K (+$14K)

0% less ownership

Funds ownership: 0.01% → 0% (-0%)

20% less funds holding

Funds holding: 5 → 4 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$10.5K
2
Morgan Stanley
Morgan Stanley
New York
+$6.17K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.03K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$33K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$85K +$2.03K +278 +3%
Invesco
2
Invesco
Georgia
$57K – – –
Morgan Stanley
3
Morgan Stanley
New York
$52K +$6.17K +843 +17%
UBS Group
4
UBS Group
Switzerland
$14K +$10.5K +1,441 +833%
Citadel Advisors
5
Citadel Advisors
Florida
– -$33K -4,328 Closed

XTLB Hedge Fund Activity: Q3 2018 in Review

4 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2018, worth a combined $208K — up 7.2% from $194K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of XTLB and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 3 added.

The largest buyer was UBS Group, adding an estimated $10.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $33K sold.

  • 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2018, down from 5 in Q2 2018.
  • Funds reported $208K of XTL Biopharmaceuticals stock for Q3 2018, up 7.2% quarter-over-quarter.
  • 0 funds opened new XTL Biopharmaceuticals positions in Q3 2018 and 1 closed out, a net change of -1 holder.
  • The largest XTL Biopharmaceuticals buyer in Q3 2018 was UBS Group, an estimated $10.5K added.
  • The largest XTL Biopharmaceuticals seller in Q3 2018 was Citadel Advisors, an estimated $33K sold.

Based on aggregated 13F filings for Q3 2018.